https://orcid.org/0000-0002-9234-1712
References
- Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520. doi:10.1182/blood-2007-10-116129
- Mateos MV, Sonneveld P, Hungria V, et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020;20(8):509–518. doi:10.1016/j.clml.2019.09.623
- Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39(10):1139–1149. doi:10.1200/JCO.20.01814
- Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895–905. doi:10.1056/NEJMoa1402888
- Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e46. doi:10.1016/S1470-2045(16)30206-6
- Blimark CH, Turesson I, Genell A, et al. Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish myeloma registry. Haematologica. 2018;103(3):506–513. doi:10.3324/haematol.2017.178103
- Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928–1937. doi:10.1200/JCO.19.02515
- Zagouri F, Kastritis E, Zomas A, et al. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. Eur J Haematol. 2017;99(5):409–414. doi:10.1111/ejh.12923
- McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279–3289. doi:10.1200/JCO.2017.72.6679
- Parrondo RD, Ailawadhi S, Sher T, Chanan-Khan AA, Roy V. Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies. JCO Oncol Pract. 2020;16(2):56–66. doi:10.1200/JOP.19.00335
- Syed YY. Lenalidomide: a review in newly diagnosed multiple myeloma as maintenance therapy after ASCT. Drugs. 2017;77(13):1473–1480. doi:10.1007/s40265-017-0795-0
- Majithia N, Rajkumar SV, Lacy MQ, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016;30(11):2208–2213. doi:10.1038/leu.2016.147
- Chalopin T, Vallet N, Theisen O, et al. No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. Br J Haematol. 2021;194:635–638. doi:10.1111/bjh.17488
- Corre J, Perrot A, Caillot D, et al. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood. 2021;137(9):1192–1195. doi:10.1182/blood.2020008346